Organ-specific proteomic aging and cognitive performance: Implications for risk prediction of Alzheimer’s disease and related dementias in older adults - 25/09/25
, Susan Baker a, Benedict Hayhoe c, Geraint Price a, Gerald Novak b, Janice Wong d, Lefkos Middleton a, Oliver Robinson a, e
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Abstract |
Background and objectives |
Biological aging, characterized by cellular and molecular changes, may play a key role in neurodegenerative diseases. While recent proteomic advancements have introduced new aging clocks, widespread validation remains necessary. This study evaluated organ-specific and cognition-enriched proteomic clocks in relation to chronological age and cognitive change.
Methods |
We analyzed plasma proteomic data from the CHARIOT PRO SubStudy (N = 409), measured using the SomaScan assay (version 4.1) at four time points over three years (months 0, 12, 24, and 36). Using published proteomic organ age weights, we calculated conventional, organ-specific, and cognition-enriched biological ages and compared them with chronological age. Adjusted multilevel regression analyses assessed associations between baseline proteomic AgeGaps (biological−chronological age differences) and cognitive performance over 54 months.
Results |
The cohort (mean age: 71.8 ± 5.5 years; 50.1 % female) showed moderate to strong correlations between proteomic ages and chronological age (r = 0.37–0.80; MAE = 4.2–2.7). Over three years, AgeGaps increased across the conventional, organismal, muscle, liver, artery, and immune systems, ranging from 2.1 ± 1.9 to 1.0 ± 2.3 years. The artery AgeGap was most strongly associated with cognitive decline, with conventional and organismal AgeGaps showing similar patterns. Higher baseline AgeGap z-scores (i.e., greater biological age) in the artery and brain were associated with poorer cognition, as measured by the Repeatable Battery for the Assessment of Neuropsychological Status Total Scores (Coeff. −3.0, 95 % CI: −3.4, −2.5; and −1.1, 95 % CI: −1.5, −0.6) and the Preclinical Alzheimer's Cognitive Composite (Coeff. −0.5, 95 % CI: −0.6, −0.4; and −0.14, 95 % CI: −0.3, −0.03).
Conclusions |
These findings highlight the interplay between neurological function and cardiovascular aging in cognitive decline. Organ-specific biological age assessments may aid in the early detection of age-related changes, informing personalized interventions. Our study underscores the importance of proteomic aging signatures in elucidating Alzheimer’s disease mechanisms and other neurodegenerative conditions, advocating for an integrated approach to brain and cardiovascular health.
Le texte complet de cet article est disponible en PDF.Keywords : Organ-specific aging, Proteomics, Biological age, Cognitive changes, Longitudinal validation, Multilevel models
Plan
Vol 12 - N° 9
Article 100274- novembre 2025 Retour au numéro
Article précédent
- A novel early imaging biomarker for glymphatic function: Cerebral cortical arterial pulsatility index from 2-Minute phase-contrast MRI
- Sung-Hye You, Byungjun Kim, Moonjung Hwang, Kyung-Sook Yang, Hye-Won Park, InSeong Kim, SuGil Kim, Kyung Min Kim, Bo Kyu Kim, Jae Ho Shin
- Temporal associations of neuropsychiatric symptoms, demographics and amyloid with subsequent tau burden in older adults
- Pablo Aguilar-Dominguez, Eleni Palpatzis, Muge Akinci, Anna Canal-Garcia, Joana B. Pereira, Alexandre Bejanin, Eider M. Arenaza-Urquijo, Alzheimer’s Disease Neuroimaging Initiative
Bienvenue sur EM-consulte, la référence des professionnels de santé.